her2-low expression in breast cancer: opportunities for expanding treatment benefit to more patients
Published 1 year ago • 2.8K plays • Length 1:20:02Download video MP4
Download video MP3
Similar videos
-
1:02:48
expanding treatment options in er /her2- breast cancer: serds, serms, sercas, and more
-
57:18
navigating the expanding treatment arsenal for er /her2- breast cancer
-
1:25:22
a new view of the spectrum of her2 expression and significance of her2 low in breast cancer
-
1:16
her2-low expression in breast cancer
-
54:02
navigating shifts in the treatment landscape for metastatic her2-positive breast cancer
-
1:13:00
expanding the benefits of parp inhibitors to more patients with breast cancer and earlier settings
-
1:30:06
moving toward expanded precision treatment of her2- or her3-driven breast, gi, lung & other cancers
-
1:35:31
leveraging targeted therapies to improve outcomes across the continuum of her2 breast cancer
-
2:21
adcs for the treatment of her2-low breast cancer
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
7:13
overview of the management of her2-low breast cancer patients
-
8:31
#esmo21 expert video report on her2-positive early breast cancer
-
4:53
comparing therapy benefit from initially her2 positive or negative metastatic breast cancer patients
-
0:52
defining her2-low breast cancer as a clinical subtype
-
0:31
remaining questions regarding her2-low breast cancer
-
1:31:37
personalizing treatment decisions in her2-altered breast cancer
-
29:21
new advances and opportunities for improvement in hr /her2- early breast cancer
-
1:36
is her2-low a distinct subtype of breast cancer?